-
1.5-([1,2,3]TRIAZOL-4-YL)-7H-PYRROLO[2,3-D]PYRIMIDINDERIVATE 有权
标题翻译: 5 - ([1,2,3]三唑-4-基)-7H-吡咯并[2,3-D] PYRIMIDINDERIVATE公开(公告)号:EP2663566A1
公开(公告)日:2013-11-20
申请号:EP11802860.4
申请日:2011-12-15
申请人: Merck Patent GmbH
IPC分类号: C07D487/02 , A61K31/437 , A61P35/00
CPC分类号: C07D487/04 , A61K31/519 , A61K45/06 , C07D487/02
摘要: Compounds of the formula (I), in which R1, R2, R2a and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours.
-
2.7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINDERIVATE 有权
标题翻译: 7 - ([1,2,3]三唑-4-基) - 吡咯[2,3-B] PYRAZINDERIVATE公开(公告)号:EP2635581A1
公开(公告)日:2013-09-11
申请号:EP11772885.7
申请日:2011-10-12
申请人: Merck Patent GmbH
IPC分类号: C07D487/04 , A61K31/437 , A61P25/00
CPC分类号: C07D487/04 , A61K31/4985 , A61K45/06
摘要: Compounds of formula I, in which R
1 , R
2 und R
3 have the meanings specified in claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be used to treat tumors.-
3.3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINDERIVATIVE 有权
标题翻译: 3 - ([1,2,3]三唑-4-基) - 吡咯[2,3-B] PYRIDINDERIVATIVE公开(公告)号:EP2427461B1
公开(公告)日:2013-10-09
申请号:EP10714187.1
申请日:2010-04-08
申请人: Merck Patent GmbH
IPC分类号: C07D471/04 , A61K31/437 , A61P35/00
CPC分类号: C07D471/04
-
公开(公告)号:EP2121682B1
公开(公告)日:2013-07-10
申请号:EP08707340.9
申请日:2008-01-28
申请人: Merck Patent GmbH
IPC分类号: C07D471/04 , A61K31/437 , A61P29/00
CPC分类号: C07D471/04
-
5.5-([1,2,3]TRIAZOL-4-YL)-7H-PYRROLO[2,3-D]PYRIMIDINDERIVATE 有权
标题翻译: 5 - ([1,2,3]三唑-4-基)-7H-吡咯并[2,3-D]嘧啶衍生物公开(公告)号:EP2663566B1
公开(公告)日:2015-06-03
申请号:EP11802860.4
申请日:2011-12-15
申请人: Merck Patent GmbH
IPC分类号: C07D487/02 , A61K31/437 , A61P35/00
CPC分类号: C07D487/04 , A61K31/519 , A61K45/06 , C07D487/02
-
6.4-(PYRROLOÝ2,3-C¨PYRIDINE-3-YL)-PYRIMIDIN-2-AMIN-DERIVATIVE 审中-公开
标题翻译: 4-(PYRROLOÝ2,3-C¨PYRIDINE-3-基) - 嘧啶-2- AMIN衍生物公开(公告)号:EP2231664A1
公开(公告)日:2010-09-29
申请号:EP08871371.4
申请日:2008-12-23
申请人: Merck Patent GmbH
IPC分类号: C07D471/04 , A61K31/437 , A61P35/00
CPC分类号: C07D471/04
摘要: The invention relates to compounds of the formula (I), where R1, R2, R3, R4, and R5 have the meanings stated in claim 1, are inhibitors of cell proliferation/cell vitality, and can be used for the treatment of tumors.
摘要翻译: 本发明涉及式(I)化合物,其中R 1,R 2,R 3,R 4和R 5具有权利要求1中所述的含义,是细胞增殖/细胞活力的抑制剂,并且可用于治疗肿瘤。
-
7.6-(PYRROLOPYRIDINYL)- PYRIMIDIN-2-YL-AMIN-DERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS UND AIDS 有权
标题翻译: 6-(吡咯并吡啶基) - 嘧啶-2-基 - 胺衍生物和它们的用于治疗癌症和AIDS的治疗中使用公开(公告)号:EP2155745A1
公开(公告)日:2010-02-24
申请号:EP08758743.2
申请日:2008-05-23
申请人: Merck Patent GmbH
发明人: DORSCH, Dieter , WUCHRER, Margarita , BURGDORF, Lars, Thore , SIRRENBERG, Christian , ESDAR, Christina , MUELLER, Thomas, J., J. , MERKUL, Eugen
IPC分类号: C07D471/04 , A61K31/437 , A61K31/506 , A61P25/00 , A61P31/18
CPC分类号: C07D471/04
摘要: The invention relates to compounds of formula (I), in which R1, R2, R3 and R4 are defined as cited in claim (1). Said compounds are inhibitors of cell proliferation and cell activity and can be used for treating tumours.
-
公开(公告)号:EP2670748B1
公开(公告)日:2016-09-28
申请号:EP12701437.1
申请日:2012-01-09
申请人: Merck Patent GmbH
发明人: DORSCH, Dieter , SIRRENBERG, Christian , MUELLER, Thomas, J.J. , MERKUL, Eugen , KARAPETYAN, Gnuni Amatunu
IPC分类号: C07D471/04 , C07D519/00 , A61K31/437 , A61P35/00
CPC分类号: C07D471/04 , A61K31/437 , A61K31/4375 , A61K45/06 , C07D519/00 , A61K2300/00
-
9.
公开(公告)号:EP2635581B1
公开(公告)日:2015-02-25
申请号:EP11772885.7
申请日:2011-10-12
申请人: Merck Patent GmbH
IPC分类号: C07D487/04 , A61K31/437 , A61P25/00
CPC分类号: C07D487/04 , A61K31/4985 , A61K45/06
-
10.6-(Pyrrolopyridinyl)- Pyrimidin-2-yl-Amin-Derivate und ihre Verwendung zur Behandlung von Krebs und Aids 有权
标题翻译: 6-(吡咯并吡啶基) - 嘧啶-2-基 - 胺衍生物和它们的用于治疗癌症和AIDS的治疗中使用公开(公告)号:EP2155745B1
公开(公告)日:2015-01-28
申请号:EP08758743.2
申请日:2008-05-23
申请人: Merck Patent GmbH
发明人: DORSCH, Dieter , WUCHRER, Margarita , BURGDORF, Lars, Thore , SIRRENBERG, Christian , ESDAR, Christina , MUELLER, Thomas, J., J. , MERKUL, Eugen
IPC分类号: C07D471/04 , A61K31/437 , A61K31/506 , A61P25/00 , A61P31/18
CPC分类号: C07D471/04
-
-
-
-
-
-
-
-
-